• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA approves intratumoral injection for dogs

December 3, 2020
dvm360 Staff
dvm360, dvm360 January 2021, Volume 52, Issue 1

Stelfonta provides an additional treatment option for local mast cell tumors on or under the skin in canine patients.

The US Food and Drug Administration (FDA) announced last month the approval of Stelfonta (tigilanol tiglate injection), the first intratumoral injection to treat nonmetastatic cutaneous mast cell tumors (MCTs) in dogs.

Stelfonta, which is injected directly into the MCT, activates a protein that spreads throughout the treated tumor and disintegrates tumor cells, according to the FDA website.

“This approval provides an additional treatment option to help treat local mast cell tumors on or under the skin in dogs,” says Steven M. Solomon, DVM, MPH, director of the FDA’s Center for Veterinary Medicine.

MCTs are the most common malignant skin tumors in dogs. Full surgical removal of mast tumor cells can be challenging when tumors are located in certain areas, like the leg. If not fully removed, the remaining malignant cells can start to grow and spread rapidly. “Stelfonta offers a novel way to treat nonmetastatic MCTs as the only approved intratumoral injection,” according to the FDA.

Stelfonta’s safety was demonstrated in a laboratory study of 118 dogs with a measurable cutaneous or a subcutaneous MCT on the lower leg. A total of 80 dogs were treated with Stelfonta, and 38 were in an untreated control group. After monitoring the dogs for a month, the complete remission rate of the treated group was 75%.

Eighteen dogs in the treatment group, whose tumors didn’t completely disappear, were retreated with Stelfonta a second time about a month after their first treatment. Approximately a month after receiving their second treatment, 44% of these dogs’ tumors had disappeared completely. Dogs in the untreated control group were treated with Stelfonta for the first time a month after the study began; 62% of those dogs’ tumors disappeared.

Advertisement

The most common adverse reactions associated with Stelfonta administration include wound formation at the tumor site and injection site reactions, such as pain, swelling, reddening of the skin, bruising, thickening, scarring, and death of some cells in the tissues.

Stelfonta is available by prescription only, as it should be administered only by veterinary personnel with the expertise to ensure safe use of the drug, assess the patient for contraindications, and monitor for adverse reactions.

Additionally, this drug should always be administered with a corticosteroid, an H1-receptor blocking agent and an H2-receptor blocking agent, thus decreasing the risk of severe systemic adverse reactions, including death, from mast cell degranulation.

The FDA also advises veterinarians to provide clients with handouts detailing important information about Stelfonta, including how to care for their pets after drug administration.

Stelfonta will be marketed in the United States by Virbac. To learn more, go here.

download issueDownload Issue: dvm360 January 2021

Related Content:

MedicalRolesAssociatesTechniciansdvm360 January 2021
Tips and tricks for diagnosing canine osteoarthritis early
Tips and tricks for diagnosing canine osteoarthritis early
Performing surgery on dogs with GDV
Performing surgery on dogs with GDV
Not-so-ordinary ER cases you should know
Not-so-ordinary ER cases you should know

Advertisement

Latest News

3 Must-reads from Fetch Charlotte 2023

A practical approach to a fever of unknown origin

Bridge Club aims to bring groomers and veterinarians together

ABVS approves full recognition for shelter medicine practice

View More Latest News
Advertisement